Lakewood-Amedex Biotherapeutics Inc.

424B4 priced

9,647,726 shares

EFFECT effective

S-1 filed

9,647,726 shares · Gross proceeds $0.00

Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company focused on developing antimicrobial therapies to combat antibiotic-resistant bacterial strains, including MRSA and VRE. The company is registering 9,647,726 shares of common stock for resale by selling stockholders, including RBW Capital Partners LLC and an investor selling stockholder. The offering includes shares from a private placement and compensation for advisory services. The company is an emerging growth company with no proceeds going to it directly. Clinical trials for its lead product, Nu-3, are ongoing, with plans for Phase 2a/2b studies to determine optimal dosing for commercialization.

424B3 priced

The current 424B3 filing updates the prospectus for Lakewood-Amedex Biotherapeutics Inc. to include information from the company's April 28, 2026 Form 8-K. The update focuses on the appointment of Dr. Joseph Tucker to the Board of Directors, his compensation structure, and related agreements. This follows the previous 424B4 filing, which outlined the company's direct listing plans and private placement of Series C Preferred Stock.

424B4 priced

4,689,177 shares

Lakewood-Amedex Biotherapeutics Inc. is conducting a direct listing on Nasdaq, allowing registered stockholders to resell up to 4,689,177 shares of common stock without a traditional IPO underwriting. The company engaged RBW Capital Partners as a financial advisor and placement agent for the listing and a private placement of Series C Preferred Stock. The direct listing structure, lack of underwriting, and reliance on a novel price-setting mechanism introduce unique risks. The company also plans to register shares underlying Series C Preferred Stock post-listing.

CERT inactive

The current filing is a Confidential Submission (CERT) for Lakewood-Amedex Biotherapeutics Inc., following a previous Notice of Effectiveness (EFFECT) on April 17, 2026. The filings indicate the company is progressing toward a potential public offering, though specific details about the offering terms, financials, or business updates are not discernible from the provided text due to formatting issues or encryption.

EFFECT effective

Lakewood-Amedex Biotherapeutics Inc. has filed an S-1 registration statement for its initial public offering (IPO), effective April 17, 2026. The filing incorporates by reference the prospectus from the company's S-1 registration statement (File No. 333-292664), which was initially filed on January 9, 2026. The previous 8-A12B filing focused on registering common stock for listing on Nasdaq, while the current S-1 represents the formal IPO registration.

8-A12B effective

Lakewood-Amedex Biotherapeutics Inc. is registering its common stock for listing on Nasdaq via a direct listing, not an underwritten IPO. The filing incorporates by reference the S-1 registration statement, confirming the company's intent to list without traditional underwriting. The registration is under Section 12(b) of the Exchange Act, with no exhibits required as no other securities are registered on Nasdaq.

S-1/A amended

4,689,177 shares · Gross proceeds $0.00

Lakewood-Amedex Biotherapeutics Inc. is conducting a direct listing on Nasdaq, enabling existing stockholders to resell up to 4,689,177 shares of common stock without a traditional IPO. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a Series C Preferred Stock private placement. The listing depends on Nasdaq approval, with shares initially priced via a novel 'Current Reference Price' mechanism. The company also plans to file a resale registration for Series C Preferred Stock and Advisory Shares post-listing.

S-1/A amended

4,689,177 shares · Gross proceeds $0.00

Lakewood-Amedex Biotherapeutics Inc. is undergoing a direct listing on Nasdaq, allowing existing shareholders to resell up to 4,689,177 shares of common stock without a traditional underwritten offering. The company has engaged RBW Capital Partners as a financial advisor and placement agent for its Series C Preferred Stock private placement. The listing process involves a novel price-setting mechanism by Nasdaq, with risks including market volatility and dependency on Nasdaq approval. The company also plans to file a resale registration for Series C Preferred Stock and Advisory Shares post-listing.

S-1/A amended

4,689,177 shares

Lakewood-Amedex Biotherapeutics Inc. is registering the resale of up to 4,689,177 shares of common stock by existing shareholders for a direct listing on Nasdaq, bypassing a traditional IPO. The company has engaged RBW Capital Partners LLC as a financial advisor and placement agent for the direct listing and a private placement of Series C Preferred Stock. The filing highlights risks related to the Nasdaq listing approval, stock price volatility, and the company's status as an emerging growth company with reduced reporting requirements.

S-1/A amended

4,689,177 shares · Gross proceeds $0.00

Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, allowing existing shareholders to resell up to 4,689,177 common shares without a traditional IPO. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock. The direct listing process involves Nasdaq's price-setting mechanism, with no underwriting. The company is an emerging growth company with reduced reporting requirements, and the listing is contingent on Nasdaq approval.

S-1/A amended

4,689,177 shares

Lakewood-Amedex Biotherapeutics Inc. is registering the resale of up to 4,689,177 shares of common stock by existing shareholders for a direct listing on Nasdaq, bypassing a traditional IPO. The company engaged RBW Capital Partners as financial advisor and placement agent for the listing and a private placement of Series C Preferred Stock. The offering is contingent on Nasdaq approval, with no assurance of success. The company is an emerging growth company with reduced reporting requirements.

S-1 filed

4,689,177 shares

Lakewood-Amedex Biotherapeutics Inc. is registering shares for a direct listing on Nasdaq, involving 4,689,177 common shares resold by existing stockholders. The offering includes a private placement of Series C Preferred Stock convertible into common shares and compensation of 269,411 advisory shares to RBW Capital Partners. The company is an emerging growth company with reduced reporting requirements, and the direct listing lacks underwriting, relying on Nasdaq's price-setting mechanism.

DRS/A amended

Lakewood-Amedex Biotherapeutics Inc. is proceeding with a direct listing on Nasdaq, registering up to 3,897,723 shares of common stock for resale by existing stockholders. The offering involves a novel approach without a firm-commitment underwriting, relying instead on Nasdaq's price-setting mechanism. The company has engaged RBW Capital Partners as a financial advisor and placement agent for a private placement of Series C Preferred Stock, convertible into common stock. The listing is conditional on Nasdaq approval, with risks including market volatility and uncertainty in the listing process.

DRS filed

Lakewood-Amedex Biotherapeutics Inc. is registering shares of common stock for a direct listing on Nasdaq, involving resale by existing stockholders without a traditional underwritten offering. The company has engaged RBW Capital Partners as a financial advisor for the listing process. The filing highlights risks related to Nasdaq approval, stock price volatility, and the company's limited operating history. No public market exists for the stock, and the direct listing structure introduces uncertainties compared to traditional IPOs.